Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded up 4% during mid-day trading on Tuesday . The stock traded as high as $44.09 and last traded at $44.00, with a volume of 187,796 shares changing hands. The stock had previously closed at $42.31.

Several equities research analysts have recently issued reports on the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, July 12th. Goldman Sachs Group Inc. reiterated a “hold” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a report on Monday, June 13th. Janney Montgomery Scott reiterated a “neutral” rating and set a $47.00 price target (down from $52.00) on shares of Agios Pharmaceuticals in a report on Monday, June 13th. JPMorgan Chase & Co. upgraded Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $50.00 to $62.00 in a report on Monday, June 13th. Finally, Canaccord Genuity upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $50.00 to $90.00 in a report on Monday, June 13th. Six investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $63.44.

The company has a 50-day moving average of $46.36 and a 200 day moving average of $45.29. The firm’s market cap is $1.67 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.18. The firm earned $31.30 million during the quarter, compared to the consensus estimate of $20.94 million. During the same period in the prior year, the company earned ($0.13) EPS. The firm’s revenue was down 8.5% compared to the same quarter last year. On average, analysts anticipate that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current year.

In related news, insider Scott Biller sold 27,500 shares of the stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the transaction, the insider now owns 81,376 shares of the company’s stock, valued at $5,289,440. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $51.69, for a total value of $129,431.76. Following the completion of the transaction, the director now directly owns 127,175 shares in the company, valued at approximately $6,573,675.75. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC boosted its position in Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 86 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock worth $1,472,000 after buying an additional 1,624 shares in the last quarter. Rhumbline Advisers boosted its position in Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock worth $1,620,000 after buying an additional 605 shares in the last quarter. ProShare Advisors LLC boosted its position in Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock worth $2,029,000 after buying an additional 1,740 shares in the last quarter. Finally, GAM Holding AG boosted its position in Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares in the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.